{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T18:33:50Z","timestamp":1791657230499,"version":"4.3.4"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.humpath.2020.09.013","type":"journal-article","created":{"date-parts":[[2020,10,2]],"date-time":"2020-10-02T18:14:04Z","timestamp":1601662444000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4905-8946","authenticated-orcid":false,"given":"Snjezana","family":"Dogan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Frosina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerica A.","family":"Geronimo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enmily","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinita","family":"Mohanty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejus","family":"Bale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn F.","family":"Hechtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Arcila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2766-243X","authenticated-orcid":false,"given":"Meera R.","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim A.","family":"Jungbluth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2020.09.013_bib1","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2020.09.013_bib2","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2020.09.013_bib3","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/path.2913","article-title":"IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours","volume":"224","author":"Amary","year":"2011","journal-title":"J Pathol"},{"key":"10.1016\/j.humpath.2020.09.013_bib4","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1634\/theoncologist.2011-0386","article-title":"Frequent mutation of isocitrate dehydrogenase (IDH) 1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping","volume":"17","author":"Borger","year":"2012","journal-title":"Oncol"},{"key":"10.1016\/j.humpath.2020.09.013_bib5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/path.4915","article-title":"Frequent IDH2 R172 mutations in undifferentiated and poorly-differentiated sinonasal carcinomas","volume":"242","author":"Dogan","year":"2017","journal-title":"J Pathol"},{"issue":"5","key":"10.1016\/j.humpath.2020.09.013_bib6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/modpathol.2016.239","article-title":"Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma","volume":"30","author":"Jo","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2020.09.013_bib7","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood-2011-11-391748","article-title":"IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma","volume":"119","author":"Cairns","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2020.09.013_bib8","doi-asserted-by":"crossref","first-page":"7118","DOI":"10.1158\/0008-5472.CAN-16-0298","article-title":"IDH2 mutations define a unique subtype of breast cancer with altered nuclear polarity","volume":"76","author":"Chiang","year":"2016","journal-title":"Canc Res"},{"key":"10.1016\/j.humpath.2020.09.013_bib9","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00401-010-0781-z","article-title":"Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas","volume":"120","author":"Hartmann","year":"2010","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.humpath.2020.09.013_bib10","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1158\/1078-0432.CCR-18-4212","article-title":"Genomic profiling identifies association of IDH1\/IDH2 mutation with longer relapse-free and metastasis-free survival in high-grade chondrosarcoma","volume":"26","author":"Zhu","year":"2020","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.humpath.2020.09.013_bib11","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1038\/s41379-019-0285-x","article-title":"DNA methylation-based classification of sinonasal undifferentiated carcinoma","volume":"32","author":"Dogan","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2020.09.013_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-06804-6","article-title":"Distinct clinical and prognostic implication of IDH1\/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma","volume":"20","author":"Ma","year":"2020","journal-title":"BMC Canc"},{"key":"10.1016\/j.humpath.2020.09.013_bib13","first-page":"1","article-title":"Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors","author":"Fan","year":"2019","journal-title":"Invest N Drugs"},{"key":"10.1016\/j.humpath.2020.09.013_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1021\/acsmedchemlett.9b00509","article-title":"Vorasidenib (AG-881): a first-in-class, brain-penetrant dual inhibitor of mutant IDH1 and 2 for treatment of glioma","volume":"11","author":"Konteatis","year":"2020","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.humpath.2020.09.013_bib15","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/ajh.24072","article-title":"Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML","volume":"90","author":"DiNardo","year":"2015","journal-title":"Am J Hematol"},{"issue":"15_suppl","key":"10.1016\/j.humpath.2020.09.013_bib16","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.7042","article-title":"Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML). ASCO","volume":"36","author":"Dinardo","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2020.09.013_bib17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/s41379-018-0126-3","article-title":"The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma","volume":"32","author":"Dogan","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.humpath.2020.09.013_bib18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmoldx.2014.12.006","article-title":"Memorial sloan kettering-integrated mutation profiling of actionable cancer targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","volume":"17","author":"Cheng","year":"2015","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2020.09.013_bib19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"10.1016\/j.humpath.2020.09.013_bib20","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bbrc.2013.01.088","article-title":"Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations","volume":"432","author":"Kaneko","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.humpath.2020.09.013_bib21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jmoldx.2018.05.012","article-title":"Multiple ways to detect IDH2 mutations in angioimmunoblastic T-cell lymphoma from immunohistochemistry to next-generation sequencing","volume":"20","author":"Dupuy","year":"2018","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.humpath.2020.09.013_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1620\/tjem.230.103","article-title":"Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations","volume":"230","author":"Kaneko","year":"2013","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.humpath.2020.09.013_bib23","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1089\/mab.2013.0050","article-title":"Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations","volume":"32","author":"Ogasawara","year":"2013","journal-title":"Monoclon Antibodies Immunodiagn Immunother"},{"key":"10.1016\/j.humpath.2020.09.013_bib24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s10014-014-0202-4","article-title":"Specific monoclonal antibodies against IDH1\/2 mutations as diagnostic tools for gliomas","volume":"32","author":"Kato","year":"2015","journal-title":"Brain Tumor Pathol"},{"key":"10.1016\/j.humpath.2020.09.013_bib25","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1111\/cas.14152","article-title":"Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants","volume":"110","author":"Gao","year":"2019","journal-title":"Canc Sci"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817720301854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817720301854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T16:37:32Z","timestamp":1758645452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817720301854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":25,"alternative-id":["S0046817720301854"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2020.09.013","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular epidemiology of IDH2 hotspot mutations in cancer and immunohistochemical detection of R172K, R172G, and R172M variants","name":"articletitle","label":"Article Title"},{"value":"Human Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.humpath.2020.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}